Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) involves the intraoperative administration of heated chemotherapeutic agents into the abdominal cavity following cytoreductive surgery (CRS). The increasing use of CRS combined with HIPEC has introduced certain procedural and physiological considerations that distinguish it from other surgical interventions, posing unique challenges for researchers and clinicians alike.
Despite advancements in surgical and anesthetic techniques, this combined approach is frequently associated with significant hemodynamic instability, coagulation abnormalities, respiratory complications, and nutritional imbalances.
The study aims to contribute to the existing body of knowledge by examining the physiological alterations induced by HIPEC, thereby offering practical insights and guidance for investigators involved in the management and study of this complex therapeutic modality.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 | Patients who will undergo HIPEC with cytoreductive surgery |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| physiological parameter ; heart rate | HIPEC is usually the application of chemotherapy that lasts between 45 and 90 minutes after the end of cytoreductive surgery. During HIPEC application (45-90 minutes), Heart rate: will be recorded every 10 minutes as beats / minute. | Intraoperatively |
| physiological parameter; systolic/diastolic blood pressure | Systolic/diastolic blood pressure will be recorded in mmHg every 10 minutes. | Intraoperatively |
| physiological parameter; SpO2 | SpO2 will be recorded as percent every 10 minutes. | Intraoperatively |
| anesthesia device measurement parameter; EtCo2 | EtCo2 will be recorded every 10 minutes as mmHg. | Intraoperatively |
| anesthesia device measurement parameter; Pmax | Pmax will be recorded as cmH2O every 10 minutes. | Intraoperatively |
| Measure | Description | Time Frame |
|---|---|---|
| Preoperative data | In the preoperative period, the patient's additional diseases, medications used, surgical history, and ASA score will be recorded. | 24 hours before surgery |
| Postoperative data |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients aged 18 years and older who are scheduled for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Miray G Özdemir | Contact | +905347816151 | miraygozdebinzet@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Miray G Özdemir | Ankara Etlik City Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ankara Etlik City Hospital | Ankara | Turkey (Türkiye) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The patient's general condition before discharge, and any complications related to surgery will be recorded.
| 24 hours after surgery |